Phenotypic Screening Services for Radiopharmaceuticals
At Rdcthera, we are a contract research organization that provides our customers with dynamic, end-to-end solutions unique in radiopharmaceuticals. We offer state-of-the-art in vitro phenotypic screening services to deliver precision, reliability, and insight to the pharmaceutical industries.
Overview of Phenotypic Screening
It is the unique property of radiopharmaceuticals that they emit radiation and can be used for diagnosis as well as therapy. However, of pivotal concern is that screening of such compounds should be done very carefully to assure their safety and efficacy. Assessment of the effect of radiopharmaceuticals on living cells may be possible by using in vitro phenotypic screening, and one could probably realize just why and through what mechanisms they work before proceeding to in vivo studies.
Fig. 1. Flow diagram of the steps of phenotypic library screening with a genomic library for identifying cancer drug target genes. (Sato M, 2020)
Personalised Comprehensive Screening Services
At Rdcthera, we offer a comprehensive range of radiopharmaceuticals screening services. Rdcthera's highly experienced team makes use of state-of-the-art equipmemt and methodologies in determining the in vitro biological activity for radiopharmaceuticals. Whether you want to determine cytotoxicity, pharmacokinetics, or target specificity for your radiopharmaceutical, we have experience in helping you achieve your objectives.
- High-Throughput Screening
Our HTS capabilities have utilized advanced automation and robotics to rapidly screen extremely large compound libraries, identifying compounds through high efficiency active compound recognition.
With detailed analysis of molecular and cellular mechanisms of action comes information useful in understanding the pharmacodynamics behind radiopharmaceuticals.
- Cytotoxicity and Viability Assays
Safety profile of compounds assessed by their cytotoxic effects on various cell lines.
Binding affinity and specificity to their target receptors are the most important factors to be measured for radiopharmaceuticals in the characterization of drug-receptor interaction.
Our Screening Methods
Our screening methods including high-throughput screening assays, cell-based assays, and imaging technologies, in assessing radiopharmaceuticals. We are well-equipped to do detailed analysis at a cellular level with respect to radiopharmaceuticals, explaining their mode of action.
- Automated Liquid Handling Systems
- High-Content Imaging Systems
- Flow Cytometry
- Radiometric Assays
Our Screening Platforms
| Oncology Platforms |
| Tumour Cell Banks |
Cell Proliferation Studies |
Cell Cycle Assays |
| Vascular Regeneration |
3D Cloning Experiments |
Cell Migration Invasion Assays |
| shRNA, RNAi, Crispr-Cas9 |
Apoptosis Assays |
Cellular RNAseq |
Immunological Platforms |
| B-cell Activity Analysis |
T-cell Activity/Proliferation |
Cytokine/Chemokine Analysis |
| Cytotoxic Effects Analysis |
Co-Culture Cells |
Peripheral Blood Single Nucleated Cell |
Metabolic Disease Platforms |
| GSIS |
3T3-L1 Differentiation |
Fatty Acid Synthesis Analysis |
| Glucose Uptake |
Thyroglobulin Assay |
CNS Platforms |
| FLIPR |
Electrophysiological Testing |
Primary Culture of Neuronal Cells |
| Ligand-Gated ion Channels |
Voltage-Gated and Ligand-Gated ion Channels |
Data and Insights
Our radiopharmaceuticals screening services will help to acquire important data related to the efficacy, safety profile, and mechanism of action for your compounds. These data are highly relevant and critical to make better decisions regarding radiopharmaceutical development and optimization in a clinical setup.
- Quantitative Analysis
- Mechanistic Insights
- Safety Profiles
In case of interest in our radiopharmaceuticals screening services, please do not hesitate to contact us today. Our experts are at hand to help you in your screening needs and accomplishment of research goals. Partner with Rdcthera for innovative solutions in radiopharmaceutical development.
Reference
- Sato M. (2020). Phenotypic screening using large-scale genomic libraries to identify drug targets for the treatment of cancer. Oncol Lett. 19(6):3617-3626.
For research use only. Not intended for any clinical use.
Related Service
